- Home
- PRQR vs CATX Comparison
PRQR vs CATX Comparison
Compare PRQR & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- CATX
- Stock Information
- Founded
- PRQR 2012
- CATX 1983
- Country
- PRQR Netherlands
- CATX United States
- Employees
- PRQR N/A
- CATX N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- PRQR Health Care
- CATX Health Care
- Exchange
- PRQR Nasdaq
- CATX Nasdaq
- Market Cap
- PRQR 244.4M
- CATX 239.0M
- IPO Year
- PRQR 2014
- CATX N/A
- Fundamental
- Price
- PRQR $2.17
- CATX $3.66
- Analyst Decision
- PRQR Strong Buy
- CATX Strong Buy
- Analyst Count
- PRQR 8
- CATX 11
- Target Price
- PRQR $8.88
- CATX $12.90
- AVG Volume (30 Days)
- PRQR 201.7K
- CATX 781.7K
- Earning Date
- PRQR 08-07-2025
- CATX 08-13-2025
- Dividend Yield
- PRQR N/A
- CATX N/A
- EPS Growth
- PRQR N/A
- CATX N/A
- EPS
- PRQR N/A
- CATX N/A
- Revenue
- PRQR $20,129,184.00
- CATX $1,471,000.00
- Revenue This Year
- PRQR N/A
- CATX N/A
- Revenue Next Year
- PRQR N/A
- CATX $11.99
- P/E Ratio
- PRQR N/A
- CATX N/A
- Revenue Growth
- PRQR 8.65
- CATX N/A
- 52 Week Low
- PRQR $1.07
- CATX $1.60
- 52 Week High
- PRQR $4.62
- CATX $16.55
- Technical
- Relative Strength Index (RSI)
- PRQR 51.89
- CATX 44.88
- Support Level
- PRQR $2.16
- CATX $3.47
- Resistance Level
- PRQR $2.15
- CATX $3.94
- Average True Range (ATR)
- PRQR 0.14
- CATX 0.24
- MACD
- PRQR -0.03
- CATX -0.08
- Stochastic Oscillator
- PRQR 42.11
- CATX 19.19
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.